institution of treatment
Showing 1 - 25 of 9,961
NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
-
Augusta, Georgia
- +40 more
Nov 29, 2023
Idiopathic Pulmonary Fibrosis Trial in Worldwide (BMS-986278, BMS-986278 Placebo)
Not yet recruiting
- Idiopathic Pulmonary Fibrosis
- BMS-986278
- BMS-986278 Placebo
-
Birmingham, Alabama
- +442 more
Aug 15, 2023
Multiple Myeloma Trial in Worldwide (Iberdomide, Lenalidomide)
Not yet recruiting
- Multiple Myeloma
-
Orange, California
- +270 more
Apr 11, 2023
Multiple Myeloma Trial in Worldwide (idecabtagene vicleucel, Lenalidomide, Fludarabine)
Not yet recruiting
- Multiple Myeloma
- idecabtagene vicleucel
- +3 more
-
Gilbert, Arizona
- +107 more
Sep 26, 2023
MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)
Not yet recruiting
- Myelodysplastic Syndromes
- Luspatercept
- Epoetin Alfa
-
Concord, California
- +100 more
Jul 20, 2023
MDS Trial in Worldwide (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Los Alamitos, California
- +53 more
Sep 13, 2023
Advanced Solid Tumors Trial in Worldwide (BMS-986466, Adagrasib, Cetuximab)
Not yet recruiting
- Advanced Solid Tumors
- BMS-986466
- +2 more
-
Birmingham, Alabama
- +24 more
Aug 29, 2023
NSCLC (NSCLC) Trial in Worldwide (nivolumab, ipilimumab, durvalumab)
Active, not recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- nivolumab
- +2 more
-
La Jolla, California
- +182 more
Feb 1, 2023
Sjögren's Syndrome Trial in Worldwide (Deucravacitinib, Placebo)
Not yet recruiting
- Sjögren's Syndrome
- Deucravacitinib
- Placebo
-
Santa Monica, California
- +25 more
Jul 19, 2023
Hepatocellular Carcinoma Trial in Worldwide (Nivolumab, Ipilimumab, Sorafenib)
Active, not recruiting
- Hepatocellular Carcinoma
- Nivolumab
- +3 more
-
Tucson, Arizona
- +209 more
Jan 17, 2023
Urinary Bladder Tumors, Muscle-Invasive Bladder Cancer Trial in Worldwide (Nivolumab, Gemcitabine, Cisplatin)
Active, not recruiting
- Urinary Bladder Neoplasms
- Muscle-Invasive Bladder Cancer
- Nivolumab
- +2 more
-
Tucson, Arizona
- +172 more
Jan 25, 2023
NSCLC Trial in Worldwide (Nivolumab, Carboplatin, Cisplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- +6 more
-
Tampa, Florida
- +112 more
Jan 30, 2023
Urothelial Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Gemcitabine)
Recruiting
- Urothelial Cancer
- Nivolumab
- +4 more
-
Birmingham, Alabama
- +196 more
Jan 17, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (CC-92480, Carfilzomib, Dexamethasone)
Recruiting
- Relapsed or Refractory Multiple Myeloma
- CC-92480
- +2 more
-
Mobile, Alabama
- +130 more
Jan 27, 2023
Palmoplantar Psoriasis, Genital Psoriasis Trial in Worldwide (Deucravacitinib, Placebo)
Not yet recruiting
- Palmoplantar Psoriasis
- Genital Psoriasis
- Deucravacitinib
- Placebo
-
Birmingham, Alabama
- +24 more
Sep 12, 2023
Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Ipilimumab, Ipilimumab )
Active, not recruiting
- Renal Cell Carcinoma
- Nivolumab
- +2 more
-
Washington, District of Columbia
- +77 more
Jan 6, 2023
Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer Trial in Worldwide (Nivolumab, Bempegaldesleukin, Radical
Active, not recruiting
- Bladder Cancer
- +2 more
- Nivolumab
- +2 more
-
Gilbert, Arizona
- +115 more
Jan 9, 2023
Clear Cell Renal Cell Carcinoma Trial in Worldwide (Nivolumab and rHuPH20, Nivolumab)
Recruiting
- Clear Cell Renal Cell Carcinoma
- Nivolumab and rHuPH20
- Nivolumab
-
Chicago, Illinois
- +104 more
Jan 13, 2023
Prostate Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Cabazitaxel)
Active, not recruiting
- Prostate Cancer
- Nivolumab
- +3 more
-
Tucson, Arizona
- +59 more
Dec 22, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)
Recruiting
- Carcinoma, Hepatocellular
- Relatlimab
- +3 more
-
Los Angeles, California
- +62 more
Feb 1, 2023